Rationale and Design of the IROCAS Study: Multicenter, International, Randomized Phase 3 Trial Comparing Adjuvant Modified (m) FOLFIRINOX to mFOLFOX6 in Patients With High-Risk Stage III (pT4 and/or N2) Colon Cancer—A UNICANCER GI-PRODIGE Trial

Jaafar Bennouna , Thierry André (1) , Loïc Campion (2) , Sandrine Hiret , Laurent Miglianico , Laurent Mineur (3) , Yann Touchefeu , Pascal Artru , Timothy Asmis , Olivier Bouché (4) , Florence Borde , Petr Kavan , You-Heng Lam , Laetitia-Shana Rajpar (5) , Jean-François Emile , Claire Jouffroy (6) , Sharlene Gill (7) , Julien Taïeb

1 SU - Sorbonne Université
2 CRCINA - Centre de Recherche en Cancérologie et Immunologie Nantes-Angers
3 Institut Sainte Catherine [Avignon]
4 Hôpital Robert Debré
5 Hôpital Louis Pasteur [Chartres]
6 UNICANCER
7 UBC - University of British Columbia

Domaines: Sciences du Vivant [q-bio]

Jaafar Bennouna, Thierry André, Loïc Campion, Sandrine Hiret, Laurent Miglianico, et al.. Rationale and Design of the IROCAS Study: Multicenter, International, Randomized Phase 3 Trial Comparing Adjuvant Modified (m) FOLFIRINOX to mFOLFOX6 in Patients With High-Risk Stage III (pT4 and/or N2) Colon Cancer—A UNICANCER GI-PRODIGE Trial. Clinical Colorectal Cancer, 2019, 18, pp.e69 - e73. ⟨10.1016/j.clcc.2018.09.011⟩. ⟨hal-03486415⟩